On July 17, 2023 ThinkCyte reported a strategic research partnership with the Institute for Molecular Medicine Finland (FIMM-HiLIFE), University of Helsinki aimed at advancing the understanding of leukemia and its treatment (Press release, University of Helsinki, JUL 17, 2023, View Source [SID1234633272]). The research partnership leverages ThinkCyte’s new artificial intelligence (AI)-driven cell characterization and sorting platform, VisionSort, with FIMM’s world renowned biorepository of clinically annotated leukemia samples and expertise in drug screening, with the aim of uncovering new insights into how to treat leukemias and other hematological malignancies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Blood cancers are a complex, heterogeneous set of diseases and while the treatment landscape has advanced in recent years, there is still a lot we don’t know," said Caroline Heckman, Research Director at FIMM. "By combining ThinkCyte’s AI-based platform to detect novel, disease-related changes in cell morphology with our curated collection of patient samples and research expertise, this approach will enable us to view these diseases and intervention strategies in an entirely new, holistic way."
FIMM hosts the Finnish Hematological Biobank, which is a national biorepository containing an extensive clinical set of leukemia sample series taken at different timepoints of disease and treatment stages (e.g. at diagnosis, remission, and relapse). By combining their technology, resources, and expertise, the groups seek to characterize how cell morphology changes in different types of blood cancer and how these changes can inform treatment selection, monitor disease progression, and aid in the identification of novel drug targets.
"We are very excited about the research partnership with FIMM, a global leader in using innovative approaches and technologies to understand and ultimately make a meaningful impact in the lives of patients with blood cancer," said Janette Phi, Chief Business Officer at ThinkCyte. "The insights we will gain from this research collaboration can be extended to many other diseases and we look forward to seeing the new avenues of R&D this collaboration will open up."